NextCure (NXTC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of two Class I Directors: Anne Borgman, M.D. and John G. Houston, Ph.D. are nominated for election.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory approval of executive compensation for named executive officers.
Approval of an amendment and restatement of the 2019 Omnibus Incentive Plan, including an increase in authorized shares for issuance.
Proxies are authorized to vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Two nominees are presented for election to the board as Class I Directors.
Executive compensation and say-on-pay
Advisory vote is sought for the compensation paid to named executive officers.
Amendment to the 2019 Omnibus Incentive Plan includes increasing the number of shares available for executive and employee incentives.
Latest events from NextCure
- Shareholders will vote on director elections, auditor ratification, executive pay, and incentive plan expansion.NXTC
Proxy filing24 Apr 2026 - Stable net loss and robust R&D investment position for major clinical milestones in 2026.NXTC
Q4 20255 Mar 2026 - NC-181 shows promise as a safer, targeted Alzheimer's therapy with IND filing set for 2025.NXTC
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference3 Feb 2026 - SIM0505 and LNCB74 advance in Phase 1, with strong efficacy and key data expected in 2026.NXTC
Corporate presentation23 Jan 2026 - LNCB74 ADC enters phase 1, with strong pipeline and $75M cash runway into 2026.NXTC
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - 338,636 shares registered for resale post-private placement and reverse split; no proceeds to issuer.NXTC
Registration Filing16 Dec 2025 - Biopharma registers 2.5M+ shares for resale post-$21.5M private placement; no resale proceeds.NXTC
Registration Filing16 Dec 2025 - Phase I ADC data expected next year; strong cash position supports pipeline and strategic focus.NXTC
Piper Sandler 37th Annual Healthcare Conference8 Dec 2025 - Key votes include director elections, auditor ratification, and a reverse stock split for Nasdaq compliance.NXTC
Proxy Filing2 Dec 2025